Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemours (CC) Cash & Equivalents (2016 - 2025)

Chemours (CC) has 11 years of Cash & Equivalents data on record, last reported at $2.0 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 99.72% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 99.72%, while the annual FY2025 figure was $2.0 million, 99.72% down from the prior year.
  • Cash & Equivalents reached $2.0 million in Q4 2025 per CC's latest filing, down from $613.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.5 billion in Q4 2021 and bottomed at $2.0 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $765.2 million, with a median of $834.0 million recorded in 2023.
  • The widest YoY moves for Cash & Equivalents: up 3246.67% in 2025, down 99.72% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $1.5 billion in 2021, then decreased by 24.05% to $1.1 billion in 2022, then rose by 9.17% to $1.2 billion in 2023, then crashed by 40.73% to $713.0 million in 2024, then plummeted by 99.72% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $2.0 million in Q4 2025, $613.0 million in Q3 2025, and $502.0 million in Q2 2025.